Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases.
The company operates through three segments: Therapeutics, Precision Medicine, and Telix Manufacturing Solutions.
It offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis.
The company's products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX007-CDx, a cold kit for the preparation of imaging for prostate cancer; TLX66-CDx to treat bone marrow conditioning.
It also TLX250 for the treatment of clear cell renal cell carcinoma; TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning.
In addition, the company develops TLX300 for the treatment of soft tissue sarcoma; TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX090, a bone-seeking agent for bone metastases and pain palliation.
Further, it operates in Australia, New Zealand, Belgium, Japan, Switzerland, Germany, the United Kingdom, Canada, Singapore, Austria, Spain, France, and the United States.
Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 22, 25 | 0.09 | - |
| Feb 20, 25 | 0.09 | - |
| Oct 17, 24 | 0.00 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 19 | 7.41 M Increased by +55.17% | -1.58 M Increased by +64.94% | Decreased by -21.33% Increased by +77.41% |
| Sep 30, 19 | 6.61 M Increased by +59.02% | 121.25 K Increased by +107.17% | Increased by +1.83% Increased by +104.51% |
| Jun 30, 19 | 5.36 M Decreased by -9.29% | 217.40 K Increased by +222.70% | Increased by +4.06% Increased by +235.27% |
| Mar 31, 19 | 5.07 M Decreased by -72.37% | -736.76 K Increased by +85.77% | Decreased by -14.53% Increased by +48.49% |
| Sep 30, 18 | 4.77 M Decreased by -63.70% | -4.51 M Decreased by -481.07% | Decreased by -94.43% Decreased by -1.15 K% |
| Jun 30, 18 | 4.16 M Decreased by -19.95% | -1.69 M Decreased by -845.89% | Decreased by -40.69% Decreased by -1.08 K% |
| Mar 31, 18 | 5.91 M Increased by +46.75% | -177.18 K Increased by +90.52% | Decreased by -3.00% Increased by +93.54% |
| Dec 31, 17 | 18.35 M Increased by +130.97% | -5.18 M Decreased by -3.32 K% | Decreased by -28.21% Decreased by -1.49 K% |